<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03593759</url>
  </required_header>
  <id_info>
    <org_study_id>UOttawaHI</org_study_id>
    <nct_id>NCT03593759</nct_id>
  </id_info>
  <brief_title>Cardiac Sarcoidosis Randomized Trial</brief_title>
  <acronym>CHASM-CS-RCT</acronym>
  <official_title>Cardiac Sarcoidosis Multi-Center Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ottawa Heart Institute Research Corporation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ottawa Heart Institute Research Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective randomized controlled trial comparing low dose Prednisone/Methotrexate
      combination to standard dose Prednisone in patients diagnosed with acute active clinically
      manifest cardiac sarcoidosis and not yet treated.

      The Investigators hypothesize that low dose Prednisone/Methotrexate combination will be as
      effective as standard dose Prednisone, and result in significantly better quality of life and
      less toxicity than standard dose Prednisone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects meeting the study inclusion/exclusion criteria will be randomized equally to receive
      either:

        1. Prednisone 0.5 mg kg/day for 6-months (MAX dose 30 mg per day) or

        2. Methotrexate 15-20 mg po, sc, or IM once a week for 6-months + Folic Acid 2 mg OD for 6
           months + Prednisone 20 mg day for 1 month, then 10 mg OD for 1 month, then 5 mg OD for
           one month then STOP

      Methotrexate will be initiated at a dose of 15 mg once a week and increased to 20 mg once a
      week after 4 weeks if tolerated. In case of Methotrexate-induced side-effects general
      guidelines will be provided, however specific management will be left to the treating
      physicians. Folic acid will be taken to help reduce methotrexate side-effects.

      Prior to randomization and study treatment all subjects will have the following baseline
      tests done: baseline safety blood work; FDG-PET scan with myocardial perfusion imaging; ECG;
      echo; and a bone scan. Cardiac MRI (CMR) is optional but strongly encouraged. Blood will be
      obtained for biomarker core-lab analysis. Biomarkers to be assayed will include highly
      sensitive Troponin I. Samples will be stored for future novel biomarker discovery. Quality of
      LIfe (QOL) questionnaires (KSQ, SAT and SF-36) will be completed prior to treatment start.

      After therapy initiation subjects will be seen at 4 weeks, 8 weeks (methotrexate arm only),
      and 12 weeks, with a final visit at 6 months. Safety bloodwork and assessment for medication
      side effects, using a medication side-effect questionnaire, will be completed at all visits.
      At 12 weeks QOL questionnaires will be completed. The primary endpoint will be assessed at
      6-months, when FDG-PET with myocardial perfusion imaging, ECG, echo, bone scan, QOL
      questionnaires, blood for biomarkers and device interrogation will be done. CMR may be
      repeated. Skin, muscle strength testing and neuropsychiatric assessment will be completed at
      6 months as part of the composite glucocorticoid toxicity index.

      After the 6 month visit. further management will be at the treating physician's discretion.
      Details of the physicians planned treatment following the 6-month PET scan will be collected.

      Standardized protocols for all aspects of FDG-PET scans (i.e. patient preparation, image
      acquisition, image processing, transfer to the core lab and analysis at core lab) will be
      followed.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 15, 2019</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective, open-label, non-inferiority, randomized controlled with blinded end-point analysis.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Summed perfusion rest score (SPRS) on FDG-PET scan</measure>
    <time_frame>6 months</time_frame>
    <description>Measure of myocardial scarring and fibrosis (blinded core lab analysis)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>6 months</time_frame>
    <description>All cause deaths</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular hospitalizations</measure>
    <time_frame>6 months</time_frame>
    <description>Cardiovascular related only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medication related adverse events</measure>
    <time_frame>6 months</time_frame>
    <description>Using clinical assessment, medication side-effect and adverse event reporting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Cleveland Clinic Glucocorticoid Toxicity Score</measure>
    <time_frame>6 months</time_frame>
    <description>Summed score of new/worsening diabetes;new/worsening HTN; osteoporosis; change in height and weight (combined and reported as BMI in kg/m2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucocorticoid Toxicity Index</measure>
    <time_frame>6 months</time_frame>
    <description>Composite scoring (improvement; no significant change; worsening) compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported symptoms related to medication</measure>
    <time_frame>6 months</time_frame>
    <description>Using medication side-effect questionnaire ( symptom present, yes or no; frequency; intensity)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medication compliance</measure>
    <time_frame>6 months</time_frame>
    <description>% of days where treatment was taken as prescribed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Generic Quality of Life (SF 36)</measure>
    <time_frame>6 months</time_frame>
    <description>Measuring general QOL using SF-36 questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Specific Quality of Life (KSQ and SAT)</measure>
    <time_frame>6 months</time_frame>
    <description>Using Kings Sarcoidosis questionnaire and Sarcoidosis Assessment Tool</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BMI</measure>
    <time_frame>6 months</time_frame>
    <description>Weight and height combined to report BMI in kg/m2, absolute and delta compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>6 months</time_frame>
    <description>Systolic and diastolic, absolute and delta compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1C</measure>
    <time_frame>6 months</time_frame>
    <description>Absolute and delta compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T-score on bone density scan</measure>
    <time_frame>6 months</time_frame>
    <description>Absolute and delta compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FDG-PET and myocardial perfusion</measure>
    <time_frame>6 month scan</time_frame>
    <description>SPRS in mismatched segments; SUVmax, SUVmean and COI; LVEF, RVEF; whole body disease activity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventricular arrhythmia burden</measure>
    <time_frame>6 months</time_frame>
    <description>Episodes of sustained ventricular arrhythmia or episodes requiring appropriate ICD therapy (shock or anti-tachycardia pacing)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete heart block</measure>
    <time_frame>6 months</time_frame>
    <description>Percentage of patients who are in CHB</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LVEF and RVEF assessed on echocardiogram</measure>
    <time_frame>6 months</time_frame>
    <description>Ejection fraction, absolute and delta compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Highly sensitive Troponin I levels and BNP levels</measure>
    <time_frame>6 months</time_frame>
    <description>Absolute and delta compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CMR Endpoints</measure>
    <time_frame>6 months</time_frame>
    <description>Volume of delayed enhancement</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">194</enrollment>
  <condition>Cardiac Sarcoidosis</condition>
  <condition>Sarcoidosis</condition>
  <arm_group>
    <arm_group_label>Prednisone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prednisone 0.5 mg kg/day for 6 months (max dose 30 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Methotrexate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Methotrexate 15-20 mg orally, sc, or IM once a week for 6 months + prednisone 20 mg po daily for one month then 10 mg po daily for one month then 5 mg po daily for one month and then stop. Also Folic Acid 2 mg po daily for 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Oral prednisone tablet</description>
    <arm_group_label>Methotrexate</arm_group_label>
    <arm_group_label>Prednisone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Oral, subcutaneous, or intramuscular methotrexate</description>
    <arm_group_label>Methotrexate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        (i) Cardiac sarcoidosis presenting with one or more of the following clinical findings:

          -  advanced conduction system disease (defined as Mobitz II AV block or third degree AV
             block)

          -  significant sinus node dysfunction (defined as average HR less than 40bpm when awake
             and/or sustained atrial arrhythmias)

          -  non- sustained or sustained ventricular arrhythmia

          -  left ventricular dysfunction (LVEF &lt; 50%)

          -  right ventricular dysfunction (RVEF &lt; 40%)

        AND

        (ii) No alternative explanation for clinical features

        AND

        (iii) FDG-PET uptake suggestive of active CS within two months of enrollment (confirmed by
        PET core lab read)

        AND ONE OR BOTH OF FOLLOWING

        (iv) Positive biopsy for Sarcoid (either EMB or extra-cardiac)

        (v) CT Chest showing features consistent with pulmonary sarcoidosis and/or mediastinal
        and/or hilar lymphadenopathy

        Exclusion Criteria:

          1. Current or recent (within two months) non-topical treatment for sarcoidosis

          2. Currently taking Methotrexate or Prednisone for another health condition

          3. Intolerance or contra-indication to Methotrexate or Prednisone

          4. Patient does not meet all of the above listed inclusion criteria

          5. Patient is unable or unwilling to provide informed consent

          6. Patient is included in another randomized clinical trial

          7. Patient has a contraindication to PET imaging or is unlikely to tolerate due to severe
             claustrophobia

          8. Pregnancy (all women of child bearing age and potential will have a negative BHCG test
             before enrollment)

          9. Breastfeeding

         10. Women of childbearing age who refuse to use a highly effective and medically
             acceptable form of contraception throughout the study

         11. Patients for whom the investigator believes that the trial is not in the interest of
             the patient
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David H Birnie, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ottawa Heart Institute Research Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David H Birnie, MD</last_name>
    <phone>613-696-7269</phone>
    <email>dbirnie@ottawaheart.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Karen MacDonald, RN</last_name>
    <phone>613-696-7000</phone>
    <phone_ext>17077</phone_ext>
    <email>kmacdonald@ottawaheart.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Michigan-Michigan Medicine Cardiovascular Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-5853</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Todd Koelling, MD</last_name>
      <phone>734-936-5265</phone>
      <email>tkoellin@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Todd Koelling, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298-0053</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jordana Kron, MD</last_name>
      <phone>804-828-7565</phone>
      <email>jordana.kron@vcuhealth.org</email>
    </contact>
    <investigator>
      <last_name>Jordana Kron, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Libin Cardiovascular Institute of Alberta</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 2T9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Russell Quinn, MD</last_name>
      <phone>403-220-5500</phone>
      <email>frquinn@ucalgary.ca</email>
    </contact>
    <investigator>
      <last_name>Russell Quinn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Paul's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mustafa Toma, MD</last_name>
      <phone>604 806 9986</phone>
      <email>MToma@providencehealth.bc.ca</email>
    </contact>
    <investigator>
      <last_name>Mustafa Toma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Eastern Health Health Sciences Centre</name>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1B 3V6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stephen Duffett, MD</last_name>
      <phone>709-777-6917</phone>
      <email>sduffett@mun.ca</email>
    </contact>
    <investigator>
      <last_name>Stephen Duffett, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Healthcare Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 4A6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nathan Hambly, MD</last_name>
      <phone>905-521-6183</phone>
      <email>nathan.hambly@medportal.ca</email>
    </contact>
    <investigator>
      <last_name>Nathan Hambly, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4A5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nikolaos Tzemos, MD</last_name>
      <phone>519-663-3038</phone>
      <email>Niko.Tzemos@lhsc.on.ca</email>
    </contact>
    <investigator>
      <last_name>Nikolaos Tzemos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Ottawa Heart Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4W7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David H Birnie, MD</last_name>
      <phone>613-696-7269</phone>
      <email>dbirnie@ottawaheart.ca</email>
    </contact>
    <investigator>
      <last_name>David Birnie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andrew Ha, MD</last_name>
      <phone>416-340-5206</phone>
      <email>andrew.ha@uhn.ca</email>
    </contact>
    <investigator>
      <last_name>Andrew Ha, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montreal Heart Institute</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 1C8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lena Rivard, MD</last_name>
      <phone>514-376-3330</phone>
      <email>lena.rivard@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Lena Rivard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CIUSSS-Hopital du Sacre-Coeur de Montreal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4J 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Leila Laroussi, MD</last_name>
      <phone>514-338-2050</phone>
      <email>liloularoussi@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Leila Laroussi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut universitaire de cardiologie et de pneumologie de Québec-Université Laval</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mario Senechal, MD</last_name>
      <email>Mario.Senechal@criucpq.ulaval.ca</email>
    </contact>
    <investigator>
      <last_name>Mario Senechal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CIUSSS de l'Estrie - CHUS - Hôpital Fleurimont</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Felix Ayala-Paredes, MD</last_name>
      <phone>819-346-1110</phone>
      <phone_ext>16317</phone_ext>
      <email>felix.ayala-paredes@USherbrooke.ca</email>
    </contact>
    <investigator>
      <last_name>Felix Ayala-Paredes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Imperial College Healthcare Trust-NHS-Hammersmith Hospital</name>
      <address>
        <city>London</city>
        <zip>W12 0HS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Amanda Varnava, MD</last_name>
      <email>amanda.varnava@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Amanda Varnava, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>June 27, 2018</study_first_submitted>
  <study_first_submitted_qc>July 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 20, 2018</study_first_posted>
  <last_update_submitted>February 20, 2020</last_update_submitted>
  <last_update_submitted_qc>February 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cardiac Sarcoidosis</keyword>
  <keyword>Prednisone</keyword>
  <keyword>Methotrexate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoidosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

